According to reports, there were 6120 new vulvar cancer cases in the United States in 20 deaths. Over the past decade, the overall incidence of vulvar cancer has increased by an average of 4.6% every five years. Vulvar cancer is a rare gynecologic malignancy, accounting for 5% of gynecologic malignancies, and it is most common in older women. Postoperative radiotherapy is not indicated for all patients with postoperative vulvar cancer and has improved survival outcomes only for patients with AJCC stage III, N1, lymph node metastases and large tumor diameter (> 3.5 cm). Further subgroup survival analysis showed that in patients with AJCC stage III, N1 stage, lymph node metastasis, and large tumor diameter (> 3.5 cm), postoperative radiotherapy resulted in a significant improvement in overall patient survival. Postoperative radiotherapy did not improve patients’ overall survival or disease-specific survival.
After propensity score matching, multivariate analysis showed that age, race, N stage, and tumor size were independent influences on overall survival and disease-specific survival of patients. The study included 3571 patients with squamous cell carcinoma of the vulva, of whom 732 (21.1%) received postoperative radiotherapy. The impact of postoperative radiotherapy on overall survival (OS) and disease-specific survival (DSS) was assessed. A propensity score matching (PSM) approach was used to balance the differences in clinicopathological characteristics between groups. MethodsĬlinical and prognostic information on patients diagnosed with vulvar squamous cell carcinoma from 2010 to 2015 was collected from the Surveillance, Epidemiology, and Prognosis (SEER) database. This study evaluated the effect of radiotherapy on the survival of patients with postoperative squamous cell carcinoma of the vulva. The role of postoperative radiotherapy in treating squamous cell carcinoma of the vulva remains controversial.
0 kommentar(er)
